GlassScriptPhysician profile
Patricia Farris
NPI 1598765893
$138,027.49
in general payments reported to CMS, 2019-2025
27 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $8,769 · 2021: $1,900 · 2022: $28K · 2023: $39K · 2024: $17K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $55K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $7,640 · Honoraria: $7,500 · Food and Beverage: $1,387 · Travel and Lodging: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $55,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,750.00 |
| Consulting Fee | $7,640.00 |
| Honoraria | $7,500.00 |
| Food and Beverage | $1,387.48 |
| Travel and Lodging | $848.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63,827.56 | 2019-2025 | |
| Allergan, INC. | $29,391.85 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22,349.29 | 2019-2025 | |
| Dermira, INC. | $20,557.60 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $432.61 | 2023 | |
| Novartis Pharmaceuticals Corporation | $243.40 | 2019-2024 | |
| Galderma Laboratories, L.P. | $157.93 | 2019-2025 | Epsolay |
| Revance Therapeutics, INC. | $142.89 | 2025 | Daxxify |
| Pfizer INC. | $126.88 | 2019-2021 | |
| Dermavant Sciences, INC. | $124.99 | 2023 | Vtama |
| Genzyme Corporation | $87.95 | 2019-2021 | |
| Incyte Corporation | $76.10 | 2024 | Opzelura |
| Solta Medical, A Division of Bausch Health US, LLC | $67.55 | 2025 | Clear+Brilliant |
| Almirall LLC | $65.27 | 2019 | |
| Merz North America, INC. | $50.93 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aclaris Therapeutics, INC. | $47.74 | 2019 | |
| Lilly USA, LLC | $47.18 | 2019-2020 | |
| Ucb, INC. | $42.47 | 2019 | |
| Mayne Pharma Commercial LLC | $33.89 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.34 | 2019 | |
| Genentech USA, INC. | $22.68 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.28 | 2020 | |
| Amgen INC. | $20.57 | 2020 | |
| Leo Pharma INC. | $15.23 | 2020 | |
| Celgene Corporation | $15.06 | 2019 | |
| Journey Medical Corporation | $14.54 | 2019 | |
| Janssen Biotech, INC. | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Farris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.